GPRC5D×CD3 TCE / Integral Molecular - LARVOL DELTA

GPRC5D multispecific antibodies: Engineering for affinity, cross-species reactivity, and bi/trispecific engagement in multiple myeloma (AACR 2026) - "GPRC5D multispecific antibodies hold promise as potent and safe therapeutics for multiple myeloma. Through CDR-Scanning, we are advancing a new generation of GPRC5D antibodies with enhanced attributes, including affinity improvements, pH sensitivity, reduced polyreactivity, improved half-life, and cross-reactivity in cynomolgus for preclinical development."

IO biomarker • Trispecific • Hematological Malignancies • Multiple Myeloma • Oncology

Updated Results of JNJ-5322, a Next-Generation BCMA×GPRC5D×CD3 Trispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (BSH 2026) - No abstract available

Clinical • Trispecific • Hematological Malignancies • Multiple Myeloma

VTS105: A novel and potent BCMA/GPRC5D/CD3 trispecific T cell engager (TCE) for the treatment of hematologic malignancies and autoimmune diseases (AACR 2025) - "Recently approved T cell engagers targeting BCMA (e.g., Teclistamab) and GPRC5D (e.g., Talquetamab) have demonstrated clinical responses; however, high relapse rates persist due to suboptimal complete response (CR) rates and minimal residual disease (MRD)...VTS105 exhibits potent human PBMC-mediated tumor cell killing across various heterogeneous MM cell lines, outperforming competitors such as JNJ-79635322, IBI3003, and SCR-8572...Evaluations in this indication are currently underway. Currently VTS105 is advancing into CMC and toxicology studies, with an Investigational New Drug (IND) filing planned for the second half of 2026."

IO biomarker • Late-breaking abstract • Trispecific • Hematological Malignancies • Multiple Myeloma • Oncology • GPRC5D

GPRC5D multispecific antibodies with potent anti-tumor activity against multiple myeloma (AACR 2025) - "GPRC5D multispecific antibodies hold promise as potent and safe therapeutics for multiple myeloma."

Hematological Malignancies • Multiple Myeloma • Oncology